Kai-Keen Shiu: NICHE2, NICHE3 and IMHOTEP summarised by Smitha Krishnamurthi
Kai-Keen Shiu shared a post on X by Smitha Krishnamurthi adding:
“NICHE2, NICHE3 and IMHOTEP beautifully summarised by Smitha Krishnamurthi
Q1: Is ctDNA prediction of pCR only relevant for NOM?
Q2: If ctDNA -ve then no adjuvant therapy needed? (I predict)
Less is more IMO + still need biomarkers CURE!”
Quoting Smitha Krishnamurthi’s post below:
“NICHE2: 3yDFS 100 % drop + rapid ctDNA clearance NICHE 3 relatlimab+nivo: 68% pCR similar to NICHE2 but numerically increased gr 3-4AE
IMHOTEP: pCR 53% with 1-2 doses pembro
Superb discussion by Jen Seligmann.”
Source: Kai-Keen Shiu/X and Smitha Krishnamurthi/X
Kai-Keen Shiu is a Medical Oncology Consultant at University College London Hospitals and Honorary Associate Professor at the UCL Cancer Institute. He specializes in oesophageal, stomach, colorectal, and hepatobiliary cancers, as well as cancers of unknown primary (CUP). Dr. Shiu leads the Cancer of Unknown Primary and Acute Oncology Services at UCLH. His research focuses on immunotherapy for gastrointestinal cancers and CUP.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023